- Home
- DSM vs CERS Comparison
DSM vs CERS Comparison
Compare DSM & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- CERS
- Stock Information
- Founded
- DSM 1989
- CERS 1991
- Country
- DSM United States
- CERS United States
- Employees
- DSM N/A
- CERS N/A
- Industry
- DSM Investment Managers
- CERS EDP Services
- Sector
- DSM Finance
- CERS Technology
- Exchange
- DSM Nasdaq
- CERS Nasdaq
- Market Cap
- DSM 280.8M
- CERS 276.0M
- IPO Year
- DSM N/A
- CERS 1997
- Fundamental
- Price
- DSM $5.97
- CERS $1.68
- Analyst Decision
- DSM
- CERS Strong Buy
- Analyst Count
- DSM 0
- CERS 2
- Target Price
- DSM N/A
- CERS $3.50
- AVG Volume (30 Days)
- DSM 161.7K
- CERS 1.6M
- Earning Date
- DSM 01-01-0001
- CERS 10-29-2025
- Dividend Yield
- DSM 3.97%
- CERS N/A
- EPS Growth
- DSM N/A
- CERS N/A
- EPS
- DSM N/A
- CERS N/A
- Revenue
- DSM N/A
- CERS $192,510,000.00
- Revenue This Year
- DSM N/A
- CERS $19.07
- Revenue Next Year
- DSM N/A
- CERS $12.03
- P/E Ratio
- DSM N/A
- CERS N/A
- Revenue Growth
- DSM N/A
- CERS 13.25
- 52 Week Low
- DSM $4.69
- CERS $1.12
- 52 Week High
- DSM $6.05
- CERS $2.24
- Technical
- Relative Strength Index (RSI)
- DSM N/A
- CERS 62.85
- Support Level
- DSM N/A
- CERS $1.46
- Resistance Level
- DSM N/A
- CERS $1.67
- Average True Range (ATR)
- DSM 0.00
- CERS 0.10
- MACD
- DSM 0.00
- CERS 0.01
- Stochastic Oscillator
- DSM 0.00
- CERS 87.95
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.